Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer
Open Access
- 1 August 2013
- journal article
- research article
- Published by Elsevier BV in The Breast
- Vol. 22, S12-S18
- https://doi.org/10.1016/j.breast.2013.08.001
Abstract
No abstract availableFunding Information
- P30 Cancer Center Grant (CA125123)
- (SPORE (CA58183)
This publication has 89 references indexed in Scilit:
- Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapyThe Breast, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K ActivationCancer Cell, 2009
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerBreast Cancer Research and Treatment, 2009
- Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K SignalingCancer Cell, 2009
- AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human CancerCancer Cell, 2009
- FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific TranscriptionCell, 2008
- A negative feedback signaling network underlies oncogene-induced senescenceCancer Cell, 2006
- Genome-wide analysis of estrogen receptor binding sitesNature Genetics, 2006